癌症治疗中奥林A的细胞和分子机制:最近的进展
Peng-Xin Wang1, Xiao-Nan Mu2, Shu-Hong Huang3
1Departments of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China; Medical College, Jining Medical University, Jining 272067, Shandong, China.
European journal of pharmacology
|February 28, 2024
概括
氧林A是一种天然化合物,通过影响细胞循环,细胞亡和炎症,显示出显著的抗瘤作用. 需要进一步的临床试验来确认其在癌症患者中的安全性和有效性.
科学领域:
- 自然产品 化学 化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统中医 (TCM) 越来越多地探索新型抗癌剂.
- 奥洛西林A (OA),来自Oroxylum indicum和Scutellaria baicalensis,表现出各种各样的生物活动.
- 在各种癌症类型的临床前研究中,OA表现有前途.
研究的目的:
- 审查Oroxylin A.的抗瘤机制.
- 评估该化合物在癌症治疗中的潜力.
- 讨论奥洛西林A的安全性和毒性概况.
主要方法:
- 对Oroxylin A的抗癌特性研究的文献综述.
- 对OA对细胞周期,细胞亡,自,炎症,糖解,血管新生,侵袭,转移和耐药性的影响进行分析.
- 对OA的安全性和毒性现有数据的检查.
主要成果:
- 奥洛西林A通过多种途径表现出抗瘤活性,包括细胞循环停止和亡诱导.
- 甲状腺炎具有抗炎,抗血管原和抗转移性质.
- 该化合物还显示出克服耐药性和抑制癌细胞糖解的潜力.
结论:
- 奥洛西林A具有广泛的抗瘤潜力.
- 进一步的研究,特别是临床试验,对于验证OA在癌症患者的治疗效益和安全性至关重要.
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


